{
    "clinical_study": {
        "@rank": "57046", 
        "arm_group": [
            {
                "arm_group_label": "Aspirin AND Lamivudine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Lamivudine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Sustained chronic  hepatitis B virus inflammation is a major cause of liver cancer\n      occurrence and development. Antiviral treatment can block the persistent infection. Aspirin\n      can inhibit platelet function and  CD8 + T cell mediated liver cell necrosis and\n      inflammation. Aspirin also can inhibit liver cancer cells  metastasis through inhibit COX2."
        }, 
        "brief_title": "Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery", 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Recurrence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Recurrence", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hepatocellular carcinoma confirmed with pathology or identified with radiological\n             images with typical features\n\n          -  Age \u2265 18 years and \u2264 75 years\n\n          -  At least one tumor nodule with one uni-dimension of \u2265 2 cm\n\n          -  Child-Pugh Class A or B\n\n          -  HBV-DNA>10^4\n\n          -  Total bilirubin \u2264 1.5 x upper limit of normal\n\n          -  ALT and AST \u2264 2.0 x the upper limit of normal\n\n          -  PT-INR<2.3,PTT < 1.5 x upper limit of normal\n\n          -  Serum creatinine \u2264 1.5x upper limit of normal\n\n          -  Peripheral white blood cell count of or more than 3\u00d710(9)/L\n\n          -  Peripheral platelet of or more than 50\u00d710(9)/L\n\n          -  Expected survival time not less than 3 months\n\n          -  ECOG score 0-2\n\n        Exclusion Criteria:\n\n          -  Tumor thrombi in main branch of portal vein\n\n          -  Tumor involvement more than 70% of whole liver\n\n          -  With extrahepatic metastasis\n\n          -  Prior systemic chemotherapy or chemoembolization\n\n          -  Congestive heart failure > NYHA class 2\n\n          -  History of HIV infection\n\n          -  Active clinically serious infections (> 2 NCI-CTC Version 3.0)\n\n          -  Recurrence of HCC after liver transplantation\n\n          -  Pregnant or breast-feeding\n\n          -  Substance abuse, medical, psychological or social conditions that may interfere with\n             the patient's participation in this study\n\n          -  Known or suspected allergy to any agent given in association with this trial\n\n          -  Patients unable to swallow oral medication\n\n          -  Inclined to thrombosis\n\n          -  Inclined to hemorrhage or active hemorrhage with 1 month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936233", 
            "org_study_id": "LC-ASPIRIN", 
            "secondary_id": "ASPIRIN-13-08"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aspirin AND Lamivudine", 
                "description": "Aspirin 0.1 QD po", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Aspirin AND Lamivudine", 
                    "Lamivudine"
                ], 
                "description": "LAminvudine 0.1 QD po", 
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Lamivudine", 
                "Antiviral Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatocellular Carcinoma", 
            "Aspirin", 
            "antiviral treatment", 
            "recurrence free survival", 
            "radical therapy"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "contact": {
                "email": "ren.zhenggang@zs-hospital.sh.cn", 
                "last_name": "Zheng-Gang Ren, Ph.D", 
                "phone": "0086-021-64041990", 
                "phone_ext": "2149"
            }, 
            "contact_backup": {
                "email": "zhang.lan@zs-hospital.sh.cn", 
                "last_name": "Lan Zhang, Master", 
                "phone": "0086-021-64041990", 
                "phone_ext": "2971"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Liver Cancer Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "ren.zhenggang@zs-hospital.sh.cn", 
            "last_name": "Zheng-Gang Ren, Ph.D", 
            "phone": "0086-021-64041990", 
            "phone_ext": "2149"
        }, 
        "overall_contact_backup": {
            "email": "zhang.lan@zs-hospital.sh.cn", 
            "last_name": "Lan Zhang, MD", 
            "phone": "0086-021-64041990", 
            "phone_ext": "2971"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "recurrence free survival", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936233"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Zheng-Gang Ren", 
            "investigator_title": "chief of departement", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "measure": "adverse  events", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}